MX2013003662A - Metodos y composiciones para diagnostico y pronostico de lesion renal e insuficiencia renal. - Google Patents

Metodos y composiciones para diagnostico y pronostico de lesion renal e insuficiencia renal.

Info

Publication number
MX2013003662A
MX2013003662A MX2013003662A MX2013003662A MX2013003662A MX 2013003662 A MX2013003662 A MX 2013003662A MX 2013003662 A MX2013003662 A MX 2013003662A MX 2013003662 A MX2013003662 A MX 2013003662A MX 2013003662 A MX2013003662 A MX 2013003662A
Authority
MX
Mexico
Prior art keywords
peptide
renal
prognosis
diagnosis
compositions
Prior art date
Application number
MX2013003662A
Other languages
English (en)
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of MX2013003662A publication Critical patent/MX2013003662A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con métodos y composiciones para monitorear, diagnóstico, pronóstico y determinación de regímenes de tratamiento en sujetos que sospechan que tienen una lesión renal. En particular, la invención se relaciona con el uso de pruebas que detectan uno o más marcadores seleccionados del grupo que consiste de factor de crecimiento Beta-nervio, Interleucina-17A, beta subunidad Folintropina, Colagenasa 3, Foliestatina, Proteína de Enlace Vitamina D, polipéptido amiloide de Islote, péptido C de Insulina, Factor H de Complemento, polipéptido inhibitorio Gástrico, péptido 1 similar al Glucagón, Glucagón, Involucrina, Queratiria-1/Queratina-10 citoqueletal Tipo II, Queratina citosqueletal Tipo II-6A/6B/6C, Osteocalcina, Lipopolisacarido, pro-hormona pancreática, Péptido YY, proteína relacionada con Agouti, factor neurotrófico ciliar, hormona regulatoria del Apetito, Transtiretina, sustrato 1 receptor de Insulina, e inhibidor alfa NF-kappa-B como pruebas de biomarcadores de diagnóstico y pronóstico en lesiones renales.
MX2013003662A 2010-10-07 2011-10-06 Metodos y composiciones para diagnostico y pronostico de lesion renal e insuficiencia renal. MX2013003662A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39099910P 2010-10-07 2010-10-07
PCT/US2011/055055 WO2012048082A2 (en) 2010-10-07 2011-10-06 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
MX2013003662A true MX2013003662A (es) 2013-05-01

Family

ID=45928428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003662A MX2013003662A (es) 2010-10-07 2011-10-06 Metodos y composiciones para diagnostico y pronostico de lesion renal e insuficiencia renal.

Country Status (12)

Country Link
US (1) US20130316370A1 (es)
EP (2) EP2625524A4 (es)
JP (3) JP2013539861A (es)
CN (1) CN103238068B (es)
AU (1) AU2011311997A1 (es)
CA (1) CA2811438A1 (es)
EA (1) EA201390293A1 (es)
HK (1) HK1186248A1 (es)
IN (1) IN2013MN00441A (es)
MX (1) MX2013003662A (es)
NZ (1) NZ608316A (es)
WO (1) WO2012048082A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3693738A1 (en) * 2013-09-20 2020-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
EP3108259B1 (en) * 2014-02-20 2018-12-05 Immundiagnostik AG In vitro diagnostic and prognosis of contrast induced nephropathy (cin) in patients undergoing coronary angiography
EP3308166A4 (en) * 2015-06-11 2019-05-15 Astute Medical, Inc. METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
CN106405064B (zh) * 2016-08-30 2018-10-26 嘉兴行健生物科技有限公司 一种40岁以上女性骨转换率的评估方法
WO2018165936A1 (zh) * 2017-03-16 2018-09-20 深圳先进技术研究院 调节能量代谢的多肽及其用途
CN109468357A (zh) * 2018-12-25 2019-03-15 河北肽都生物科技有限公司 一种脾氨肽的制备方法
KR20220041883A (ko) * 2019-07-26 2022-04-01 펀다시오 인스티튜트 드’인베스티가시오 바이오메티칼 드 벨리비티게 (아이디벨) 에르고티오네인, s-메틸-에르고티오네인 및 이들의 용도
CN113092768A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液角蛋白,ii型细胞骨架1及其多肽片段在过敏性疾病中的应用
CN114264828B (zh) * 2022-01-28 2023-09-08 中国科学院基础医学与肿瘤研究所(筹) 鉴别良性甲状腺结节与甲状腺癌的生物标志物及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
ES2150915T3 (es) 1991-04-12 2000-12-16 Biosite Diagnostics Inc Nuevos conjugados y dosificados destinados para la deteccion simultanea de ligandos multiples.
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP4487376B2 (ja) * 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
JP2002191398A (ja) * 2000-12-26 2002-07-09 Jenokkusu Soyaku Kenkyusho:Kk アレルギー性疾患検査方法
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2005000194A2 (en) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
US6941172B2 (en) * 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
AU2005233212A1 (en) * 2004-04-16 2005-10-27 Monash University A method for monitoring the progress of cancer
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
US7955805B2 (en) * 2004-12-15 2011-06-07 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing complications of pregnancy
ES2818028T3 (es) * 2004-12-20 2021-04-09 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
US20070087387A1 (en) * 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
JP2007057509A (ja) * 2005-08-26 2007-03-08 Toray Ind Inc ネコアクチビンａの測定方法およびその測定キット
WO2007106781A2 (en) * 2006-03-10 2007-09-20 University Of Rochester Ecg-based differentiation of lqt1 and lqt2 mutation
US20090311193A1 (en) * 2006-03-23 2009-12-17 Invitrogen Corporation Methods and reagents for in vivo imaging of cancer cell lines
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
EP2479569A3 (en) * 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
WO2008150488A1 (en) * 2007-06-01 2008-12-11 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
US8039227B2 (en) * 2007-09-20 2011-10-18 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20110287964A1 (en) * 2008-11-17 2011-11-24 The Brigham And Women's Hospital, Inc. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans
ES2528799T3 (es) * 2008-11-22 2015-02-12 Astute Medical, Inc. Métodos para el pronóstico de insuficiencia renal aguda
JP2012517594A (ja) * 2009-02-06 2012-08-02 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法および組成物
US20120052512A1 (en) * 2009-02-06 2012-03-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9029093B2 (en) * 2010-02-26 2015-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Also Published As

Publication number Publication date
CN103238068A (zh) 2013-08-07
EA201390293A1 (ru) 2013-09-30
US20130316370A1 (en) 2013-11-28
JP6321080B2 (ja) 2018-05-09
JP2018141793A (ja) 2018-09-13
CN103238068B (zh) 2016-06-08
JP2013539861A (ja) 2013-10-28
IN2013MN00441A (es) 2015-05-29
NZ608316A (en) 2015-03-27
CA2811438A1 (en) 2012-04-12
HK1186248A1 (zh) 2014-03-07
EP2625524A4 (en) 2014-05-07
JP2016180762A (ja) 2016-10-13
WO2012048082A3 (en) 2012-06-21
AU2011311997A1 (en) 2013-04-04
WO2012048082A2 (en) 2012-04-12
EP2625524A2 (en) 2013-08-14
EP3249402A1 (en) 2017-11-29

Similar Documents

Publication Publication Date Title
MX2013003662A (es) Metodos y composiciones para diagnostico y pronostico de lesion renal e insuficiencia renal.
De Boer et al. Galectin‐3 in heart failure with preserved ejection fraction
PH12017501252A1 (en) Gip and glp-1 co-agonist compounds.
Bergmann et al. Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers?
WO2008061149A3 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
TW200726845A (en) Biomarker molecular of renal illness and detecting method for the same
WO2008084331A3 (en) Biomarkers for renal disorders
BRPI0716811B8 (pt) anticorpos antirreceptor alfa de folato humano,usos e método de produção dos mesmos, coquetel dos mesmos, vetor de expressão, microrganismo hospedeiro, composição e combinação farmacêuticas, e método para o diagnóstico ou reprodução de imagens de carcinoma ovariano ou suas metástases
IN2012DN01322A (es)
WO2012170438A3 (en) HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR
WO2009101059A3 (en) Methods of using cadherin 11 (cdh11) antagonists
GB0510511D0 (en) Diagnosis of tuberculosis
MX2012001559A (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
Narayan et al. Plasma homocysteine levels in depression and schizophrenia in South Indian Tamilian population
Reid et al. The effect of bariatric surgery on renal function
WO2008144761A3 (en) Methods and compositions for identifying and treating lupus
Onur et al. A decreased serum omentin-1 level may be an independent risk factor for peripheral arterial disease.
CL2007003513A1 (es) Kit para la deteccion de un peptido diana seleccionado del grupo del peptido beta-amiloide (ab) ab42, ab40 y la combinacion de ambos; y su uso para el diagnostico de un trastorno degenerativo en un sujeto.
BR112012011598A2 (pt) polipeptídeos de haemophilus parasuis e métodos de uso
Wang et al. Profiling analysis reveals the potential contribution of peptides to human adipocyte differentiation
WO2012112013A3 (en) A marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer
Zygulska et al. Enterohormonal disturbances in colorectal cancer patients.
Boeckxstaens Neuroimmune interaction in the gut: from bench to bedside.
Nishi et al. Laboratory and imaging features of kidney involvement in autoimmune pancreatitis: incidence, correlation, and steroid therapy response.
WO2009079566A3 (en) Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production

Legal Events

Date Code Title Description
FA Abandonment or withdrawal